Compare Amphastar Pharmaceuticals Inc (AMPH) vs Zillow Group Inc Class C (Z) Price & Performance

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Zillow Group (Z) trades at $33.61, up 0.54% on the day, amid a challenging real estate market. The stock faces a bearish technical signal with support at $33 and resistance at $34. Fundamentally, the company shows improving revenue and a return to profitability in 2025, with a net income of $23 million, though valuation ratios like a P/E of 146.74 remain high. Recent news is dominated by a securities class action lawsuit with a deadline of August 10, 2026, creating significant headline risk.

The outlook is cautious. While analyst consensus is a Buy with a $47.00 price target, indicating potential upside, near-term risks from the lawsuit and a bearish technical picture suggest volatility. Investment opportunity hinges on the company's ability to sustain revenue growth and improve margins, but investors must weigh the legal overhang and high valuation against the positive earnings trajectory.